Category: Treatment

LitAlert ~~ GeneLit.com

    • Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
    • Chen H, Liu Y, Yin Z, Chen H, Wang Y, Qian Y.
    • Cell Cycle. 2023 Feb 9:1-24. doi: 10.1080/15384101.2023.2174339. Epub ahead of print.

    • Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer.
    • Huang Y, Liu C, You L, Li X, Chen G, Fan J.
    • J Cell Mol Med. 2023 Feb 8. doi: 10.1111/jcmm.17683. Epub ahead of print.

    • Dr. Choudhury on the Potential Benefit of PARP Inhibitor Use in mCRPC.
    • Choudhury AD.
    • OncLive. OncLive TV. 2023 Feb 8.

    • A matched case-control study of the prognosis of early breast cancer in patients with Li-Fraumeni syndrome (BREAST TP53).
    • Petry V, Colombo Bonadio R, Testa L, Cohn DJBH, Cagnacci A, Campos RG, Cândida Bv Fragoso M, del Pilar Estevez-Diz M.
    • Breast. 2023 Feb 6:S0960-9776(23)00025-5. doi: 10.1016/j.breast.2023.02.002. Epub ahead of print.

    • Sacituzumab govitecan in metastatic, triple-negative, BRCA-mutant breast cancer patient with active brain metastases: a case report.
    • Di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, Laganà M, Grisanti S, Cosentini D, Berruti A.
    • Front Oncol. 2023 Feb 6;13:1139372. doi: 10.3389/fonc.2023.1139372.

    • Pyrosequencing assay for BRCA1 methylation analysis: results from a cross-validation study.
    • Sahnane N, Rivera D, Libera L, Carnevali I, Banelli B, Facchi S, Gismondi V, Paudice M, Cirmena G, Vellone VG, Sessa F, Varesco L, Tibiletti MG.
    • J Mol Diagn. 2023 Feb 3:S1525-1578(23)00005-3. doi: 10.1016/j.jmoldx.2023.01.003. Epub ahead of print.

    • Homologous Recombination Deficiency in Ovarian Cancer: From the Biological Rationale to Current Diagnostic Approaches.
    • Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, Malapelle U, Biffi S.>
    • J Pers Med. 2023 Feb 2;13(2):284. doi: 10.3390/jpm13020284.

    • Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
    • Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL.
    • JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.

    Related:

    •• Identifier: NCT02693535: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR). (ClinicalTrials.gov . Accessed 2023 Feb 8.)

    • BRCA1/2 pathogenic variants are not common in Merkel cell carcinoma: Comprehensive molecular study of 30 cases and meta-analysis of the literature.
    • Gaubert A, Kervarrec T, Montaudié H, Burel-Vandenbos F, Cardot-Leccia N, Di Mauro I, Fabas T, Tallet A, Kubiniek V, Pedeutour F, Dadone-Montaudié B.
    • J Invest Dermatol. 2023 Feb 6:S0022-202X(23)00068-4. doi: 10.1016/j.jid.2023.01.014. Epub ahead of print.

    • Germline TP53 pathogenic variants and breast cancer: A narrative review.
    • Blondeaux E, Arecco L, Punie K, Graffeo R, Toss A, De Angelis C, Trevisan L, Buzzatti G, Linn SC, Dubsky P, Cruellas M, Partridge AH, Balmaña J, Paluch-Shimon S, Lambertini M.
    • Cancer Treat Rev. 2023 Jan 31;114:102522. doi: 10.1016/j.ctrv.2023.102522. Epub ahead of print.

    • Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
    • Zheng J, Li Z, Min W.
    • Front Pharmacol. 2023 Jan 23;13:979873. doi: 10.3389/fphar.2022.979873.

    • Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.
    • Yu L, Lin J, Li H, Sun L, Wang S, Chen Y, Chen H, Lin L.
    • Front Pharmacol. 2023 Jan 23;14:997760. doi: 10.3389/fphar.2023.997760.

    • A Case of Metastatic Thymoma Responsive to Treatment With 177Lu-DOTATATE.
    • Halperin R, Urban D, Tirosh A.
    • Clin Nucl Med. 2023 Jan 13. doi: 10.1097/RLU.0000000000004553. Epub ahead of print.
    • Case report

    • A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer.
    • Yildirim HC, Ismayilov R, Akyildiz A, Guven DC, Abdurrahimli N, Dizdar O, Yalcin S.
    • Anticancer Drugs. 2022 Dec 19. doi: 10.1097/CAD.0000000000001486. Epub ahead of print.
    • Case report

    • Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis.
    • Yang Y, Yang X, Li H, Tong X, Zhu X.
    • J Obstet Gynaecol. 2023 Dec;43(1):2151883. doi: 10.1080/01443615.2022.2151883. Epub 2022 Dec 9.

    • Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
    • Li Y.
    • J Obstet Gynaecol. 2023 Dec;43(1):2171282. doi: 10.1080/01443615.2023.2171282.

    • LitAlert ~~ GeneLit.com

    • Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
    • Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, Valabrega G.
    • Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032.

    • Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: JGOG3025 study.
    • Yoshihara K, Baba T, Tokunaga H, Nishino K, Sekine M, Takamatsu S, Matsumura N, Yoshida H, Kajiyama H, Shimada M, Kagimura T, Oda K, Sasajima Y, Yaegashi N, Okamoto A, Sugiyama T, Enomoto T.
    • Cancer Sci. 2023 Feb 6. doi: 10.1111/cas.15747. Epub ahead of print.

    Related:

    •• Identifier: NCT03159572: Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (HITOMI). (ClinicalTrials.gov . Accessed 2023 Feb 7.)

    • Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.
    • Jia B, Xia P, Dong J, Feng W, Wang W, Liu E, Jiang G, Qin Y.
    • Front Oncol. 2023 Jan 17;12:1086908. doi: 10.3389/fonc.2022.1086908.

    • LitAlert ~~ GeneLit.com

    • Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer.
    • King D, Scott R.
    • OncLive. 2023 Feb 5.

    • Mitigating fear of cancer recurrence.
    • Sorscher S.
    • Breast Cancer Res Treat. 2023 Feb 3. doi: 10.1007/s10549-022-06824-9. Epub ahead of print.

    • Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice.
    • Yamai T, Ikezawa K, Sugimoto N, Urabe M, Kai Y, Takada R, Nakabori T, Uehara H, Kawamura T, Kunimasa K, Yamamoto S, Wakamatsu T, Hayashi T, Kukita Y, Fujisawa F, Inoue T, Yamaguchi Y, Yamasaki T, Honma K, Ohkawa K.
    • Cancers (Basel). 2023 Feb 3;15(3):970. doi: 10.3390/cancers15030970.

    • Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC.
    • Wahner A.
    • OncLive. 2023 Feb 1.

    • The Role of PARP Inhibitors in Non-BRCA Mutated Breast Cancer.
    • Ballinger TJ.
    • Medscape Oncology. Decision Point. 2023 Jan 13.

    • Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
    • Kim ET, Jeong HE, Yoon HJ, Kim KH, Suh DS.
    • Taiwan J Obstet Gynecol. 2023 Jan;62(1):66-70. doi: 10.1016/j.tjog.2022.07.010.

    • Homologous Recombination Deficiency in Ovarian Cancer: From the Biological Rationale to Current Diagnostic Approaches.
    • Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, Malapelle U, Biffi S.>
    • J Pers Med. 2023 Feb 2;13(2):284. doi: 10.3390/jpm13020284.

    • LitAlert ~~ GeneLit.com

    • Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC.
    • Wahner A.
    • OncLive. 2023 Feb 1.

    • Dr. King on Delays in Access to Germline Testing in Pancreatic Cancer.
    • King D.
    • OncLive. OncLive TV. 2023 Jan 31.

    • The Role of PARP Inhibitors in Non-BRCA Mutated Breast Cancer.
    • Ballinger TJ.
    • Medscape Oncology. Decision Point. 2023 Jan 13.

    • LitAlert ~~ GeneLit.com

    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
    • Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ.
    • Oncologist. 2023 Jan 30:oyac275. doi: 10.1093/oncolo/oyac275. Epub ahead of print.

    Related:

    •• Identifier: NCT01033123: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    •• Identifier: NCT01033292: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    • Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I.
    • JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258.

    Related:

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 30.)

    • LitAlert ~~ GeneLit.com

    • Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
    • Heitz F, Ataseven B, Staniczok C, Denkert C, Rhiem K, Hahnen E, Heikaus S, Moubarak M, Welz J, Dagres T, Vrentas V, Bommert M, Schneider S, Concin N, Harter P.
    • Cancers (Basel). 2023 Jan 29;15(3):818. doi: 10.3390/cancers15030818.

    • PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
    • Chelariu-Raicu A, Trillsch F, Burges A, Czogalla B, Hester A, Wuerstlein R, Harbeck N, Mahner S.
    • Int J Gynecol Cancer. 2023 Jan 27:ijgc-2022-003990. doi: 10.1136/ijgc-2022-003990. Epub ahead of print.
    • Review

    • Pairing tumor testing with germline sequencing increases the number of pathogenic germline variants identified. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Nefeli Dimopoulos C, Brierly K, Gibson J, Walther Z, Llor X.
    • Fam Cancer. [P-32: Research Categories» Gastric cancer-related syndromes.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract

    • LitAlert ~~ GeneLit.com

    • PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
    • Chelariu-Raicu A, Trillsch F, Burges A, Czogalla B, Hester A, Wuerstlein R, Harbeck N, Mahner S.
    • Int J Gynecol Cancer. 2023 Jan 27:ijgc-2022-003990. doi: 10.1136/ijgc-2022-003990. Epub ahead of print.
    • Review

    • Pairing tumor testing with germline sequencing increases the number of pathogenic germline variants identified. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Nefeli Dimopoulos C, Brierly K, Gibson J, Walther Z, Llor X.
    • Fam Cancer. [P-32: Research Categories» Gastric cancer-related syndromes.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract

    • LitAlert ~~ GeneLit.com

    • Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
    • Bourien H, Lefevre LB, Mouret-Reynier MA, Asselain B, Lucas B, Gavoille C, Cornila C, Gavoille L, Colomba E, Patsouris A, Fabbro M, Chakiba C, Toussaint P, Simon H, Berton D, Garbay D, Tixidre CG, Coeffic D, Morvan A, Collard O, DE LA Motte Rouge T.
    • Anticancer Res. 2023 Feb;43(2):653-662. doi: 10.21873/anticanres.16202.

    • Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer.
    • Liu J, Mroczek M, Mach A, Stępień M, Aplas A, Pronobis-Szczylik B, Bukowski S, Mielczarek M, Gajewska E, Topolski P, Król ZJ, Szyda J, Dobosz P.
    • Cancers (Basel). 2023 Jan 27;15(3):779. doi: 10.3390/cancers15030779.

    • LitAlert ~~ GeneLit.com

    • Genetic Testing Challenges in Oncology: Patient With Pending Bill Has BRCA1 Result Withheld.
    • Ray T.
    • Precision Oncology News. 2023 Jan 23.

    • Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
    • Nie J, Wu H, Sun L, Ding Y, Luan Y, Wu J.
    • Front Pharmacol. 2023 Jan 4;13:987337. doi: 10.3389/fphar.2022.987337.

    • Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
    • Drogan CM, Kindler HL, Gao G, Kupfer SS.
    • JCO Precis Oncol. 2023 Jan;7:e2200196. doi: 10.1200/PO.22.00196.